Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs

被引:54
作者
Demir, Lutfiye [1 ]
Yigit, Seyran [2 ]
Ellidokuz, Hulya [3 ]
Erten, Cigdem [1 ]
Somali, Isil [4 ]
Kucukzeybek, Yuksel [1 ]
Alacacioglu, Ahmet [1 ]
Cokmert, Suna [1 ]
Can, Alper [1 ]
Akyol, Murat [1 ]
Dirican, Ahmet [1 ]
Bayoglu, Vedat [1 ]
Sari, Aysegul Akder [2 ]
Tarhan, Mustafa Oktay [1 ]
机构
[1] Izmir Katip Celebi Univ, Dept Med Oncol, Ataturk Training & Res Hosp, TR-35360 Izmir, Turkey
[2] Izmir Katip Celebi Univ, Dept Pathol, Ataturk Training & Res Hosp, TR-35360 Izmir, Turkey
[3] Dokuz Eylul Univ, Dept Prevent Oncol, Inst Oncol, Izmir, Turkey
[4] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, Izmir, Turkey
关键词
Breast cancer; FOXP3+T lymphocytes; Neoadjuvant chemotherapy; Pathologic complete response; PATHOLOGICAL COMPLETE RESPONSE; REGULATORY T-CELLS; NEOADJUVANT-CHEMOTHERAPY; LYMPHOCYTE INFILTRATION; IMMUNE-RESPONSE; TUMOR; DOXORUBICIN; EXPRESSION; CYCLOPHOSPHAMIDE; STAGE;
D O I
10.1007/s10585-013-9602-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
This study aimed to investigate the prognostic and predictive effect of FOXP3+ Tregs together with clinicopathologic factors in locally advanced breast cancer (LABC) patients. The medical records of 101 LABC patients who received neoadjuvant chemotherapy (NAC) between 2005 and 2012 were evaluated retrospectively. The density of intratumoral FOXP3+ lymphocytes in paraffin-embedded tissues was assessed by immunohistochemical analyses in appropriate cases. The relationship with clinicopathologic features, prognosis and chemotherapy response was investigated. HR(-) and HER2(+) tumors tended to have higher pre-chemotherapy Tregs than HR(+) tumors, and significantly higher pathologic complete response (PCR) rates were observed in these patients. Treg decline after NAC was associated with better pathological response rates. Lower intratumoral infiltration of FOXP3+ Tregs after NAC (< 3.4/HPF) was significantly associated with higher PCR rates for breast, and close to the significance limit for total (or both for breast and axillary) PCR rates (PCR for breast: 25 vs. 2.9 % for low vs. high Treg, p = 0.001; PCR for breast + axillary tissue: 13.9 vs. 0 %, p = 0.05). Despite better PCR rates, patients with high intratumoral Treg infiltrates (a parts per thousand yen11.5/HPF) before chemotherapy had significantly shorter overall survival than patients with low Treg infiltrates (< 11.5/HPF). Cox multivariate regression analyses demonstrated that the density of Treg infiltration before chemotherapy was the strongest predictor for survival. This study established the predictive and prognostic effect of intratumoral FOXP3+ Tregs in LABC patients. To predict clinical outcome, evaluation of FOXP3+ Tregs in tumoral tissues before and after NAC should be considered for these high-risk patients.
引用
收藏
页码:1047 / 1062
页数:16
相关论文
共 47 条
[1]
Towards a novel classification of human malignancies based on gene expression patterns [J].
Alizadeh, AA ;
Ross, DT ;
Perou, CM ;
van de Rijn, M .
JOURNAL OF PATHOLOGY, 2001, 195 (01) :41-52
[2]
[Anonymous], 2010, CANC STAGING MANUAL
[3]
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Smith, RE ;
Geyer, CE ;
Mamounas, EP ;
Fisher, B ;
Brown, AM ;
Robidoux, A ;
Margolese, R ;
Kahlenberg, MS ;
Paik, S ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027
[4]
Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target [J].
Bohling, Sandra D. ;
Allison, Kimberly H. .
MODERN PATHOLOGY, 2008, 21 (12) :1527-1532
[5]
The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer [J].
Canna, K ;
McArdle, PA ;
McMillan, DC ;
McNicol, AM ;
Smith, GW ;
McKee, RF ;
McArdle, CS .
BRITISH JOURNAL OF CANCER, 2005, 92 (04) :651-654
[6]
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy [J].
Colleoni, M. ;
Viale, G. ;
Zahrieh, D. ;
Bottiglieri, L. ;
Gelber, R. D. ;
Veronesi, P. ;
Balduzzi, A. ;
Torrisi, R. ;
Luini, A. ;
Intra, M. ;
Dellapasqua, S. ;
Cardillo, A. ;
Ghisini, R. ;
Peruzzotti, G. ;
Goldhirsch, A. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :465-472
[7]
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy [J].
Darb-Esfahani, Silvia ;
Loibl, Sibylle ;
Mueller, Berit M. ;
Roller, Marc ;
Denkert, Carsten ;
Komor, Martina ;
Schluens, Karsten ;
Blohmer, Jens Uwe ;
Budczies, Jan ;
Gerber, Bernd ;
Noske, Aurelia ;
du Bois, Andreas ;
Weichert, Wilko ;
Jackisch, Christian ;
Dietel, Manfred ;
Richter, Klaus ;
Kaufmann, Manfred ;
von Minckwitz, Gunter .
BREAST CANCER RESEARCH, 2009, 11 (05)
[8]
Prognostic value of initial clinical disease stage after achieving pathological complete response [J].
Dawood, Shaheenah ;
Broglio, Kristine ;
Kau, Shu-Wan ;
Islam, Rabiul ;
Symmans, W. Fraser ;
Buchholz, Thomas A. ;
Mcguire, Sean E. ;
Meric-Bernstam, Funda ;
Cristofanilli, Massimo ;
Hortobagyi, Gabriel N. ;
Gonzalez-Angulo, Ana M. .
ONCOLOGIST, 2008, 13 (01) :6-15
[9]
The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer [J].
de Kruijf, Esther M. ;
van Nes, Johanna G. H. ;
Sajet, Anita ;
Tummers, Quirijn R. J. G. ;
Putter, Hein ;
Osanto, Susanne ;
Speetjens, Frank M. ;
Smit, Vincent T. H. B. M. ;
Liefers, Gerrit Jan ;
van de Velde, Cornelis J. H. ;
Kuppen, Peter J. K. .
CLINICAL CANCER RESEARCH, 2010, 16 (04) :1272-1280
[10]
Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression [J].
DeNardo, David G. ;
Coussens, Lisa M. .
BREAST CANCER RESEARCH, 2007, 9 (04)